Abstract
ABC-transporters have been recognized as being responsible for multiple drug resistance in tumor therapy, for decreased brain uptake and low oral bioavailability of drug candidates, and for drug-drug interactions and drug induced cholestasis. P-glycoprotein (ABCB1), the paradigm protein in the field, is mainly effluxing natural product toxins and shows very broad substrate specificity. Within this article we will highlight SAR and QSAR approaches for designing natural product type inhibitors of ABCB1 and related proteins as well as in silico strategies to predict ABCB1 substrates and inhibitors in order to design out undesirable drug/protein interaction.
Keywords: Natural products, ABC transporter, P-glycoprotein, in silico methods
Current Pharmaceutical Design
Title: Pharmacoinformatic Approaches to Design Natural Product Type Ligands of ABC-Transporters
Volume: 16 Issue: 15
Author(s): F. Klepsch, I. Jabeen, P. Chiba and G. F. Ecker
Affiliation:
Keywords: Natural products, ABC transporter, P-glycoprotein, in silico methods
Abstract: ABC-transporters have been recognized as being responsible for multiple drug resistance in tumor therapy, for decreased brain uptake and low oral bioavailability of drug candidates, and for drug-drug interactions and drug induced cholestasis. P-glycoprotein (ABCB1), the paradigm protein in the field, is mainly effluxing natural product toxins and shows very broad substrate specificity. Within this article we will highlight SAR and QSAR approaches for designing natural product type inhibitors of ABCB1 and related proteins as well as in silico strategies to predict ABCB1 substrates and inhibitors in order to design out undesirable drug/protein interaction.
Export Options
About this article
Cite this article as:
Klepsch F., Jabeen I., Chiba P. and Ecker G. F., Pharmacoinformatic Approaches to Design Natural Product Type Ligands of ABC-Transporters, Current Pharmaceutical Design 2010; 16 (15) . https://dx.doi.org/10.2174/138161210791163992
DOI https://dx.doi.org/10.2174/138161210791163992 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nanocarriers for Anticancer Drugs - New Trends in Nanomedicine
Current Drug Metabolism Development of Furo[2,3-b]quinoline Derivatives with Anti-Breast Cancer Property by Targeting Topoisomerase II
Anti-Cancer Agents in Medicinal Chemistry Anti-Carcinogenic Effects of Carnosol-An Updated Review
Current Drug Discovery Technologies Central Composite Designed Imatinib-Loaded Magnetic Nanoparticles
Current Nanomedicine Vitamin D and Metabolic Syndrome: Is There a Link?
Current Pharmaceutical Design Meet Our Regional Editor
Current Bioinformatics An Optimized Approach for Breast Cancer Classification for Histopathological Images Based on Hybrid Feature Set
Current Medical Imaging The FDG-PET Revolution of Medical Imaging – Four Decades and Beyond
Current Molecular Imaging (Discontinued) Molecular Link Mechanisms between Inflammation and Cancer
Current Pharmaceutical Design The Potential for Targeting Oncogenic WNT/β -Catenin Signaling in Therapy
Current Drug Targets Tumor Stroma as a Target in Cancer
Current Cancer Drug Targets Evaluation of a New <sup>99m</sup>Tc-labeled GnRH Analogue as a Possible Imaging Agent for Prostate Cancer Detection
Anti-Cancer Agents in Medicinal Chemistry Design and Pre-Clinical Development of Epitope-based DNA Vaccines Against B-Cell Lymphoma
Current Gene Therapy Potential Benefits of Glitazones for Cancer and Vascular Disease
Current Drug Therapy Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry To Preliminarily Evaluate The Anticancer Activiy of 1,2-di(quinazolin-4- yl)diselane Against MDA-MB-435 Cells in vitro
Letters in Drug Design & Discovery Antitumor Potential and Possible Targets of Phenothiazine-Related Compounds
Current Drug Targets EGFR-Targeting Monoclonal Antibodies in Head and Neck Cancer
Current Cancer Drug Targets Current and Potential Chemotherapeutic Agents Used for Induction Chemotherapy in the Treatment of Breast Cancer
Current Pharmaceutical Design Ovarian Toxicity: From Environmental Exposure to Chemotherapy
Current Pharmaceutical Design